Overview: Galectin-glycan Interactions in Immune Function {#s1}
=========================================================

Galectins are a family of evolutionarily conserved glycan binding proteins (lectins) widely expressed in both stromal and immune tissues ([@B1]). In immunity, extensive research has established galectins as important regulators of immune homeostasis ([@B2]), inflammation ([@B3]), malignancy ([@B4]--[@B6]), and autoimmune disease ([@B7]). In the innate immune system, galectins are known to regulate granulocyte chemotaxis, dendritic cell maturation, mast cell activation, and many other activities ([@B3]). However, galectins are perhaps most widely recognized for their effects on T lymphocyte function, where galectins (Gal)-1,-3, and -9 have been shown to differentially modulate development, activation, differentiation, and effector function ([@B3], [@B8], [@B9]). The roles of galectins in innate and cell-mediated adaptive immunity have been reviewed at length elsewhere ([@B1]--[@B4], [@B7], [@B8]). Yet, while significant progress has been made in deciphering roles of galectins in innate immune cell and T cell biology, the roles for galectins in B cells have only recently begun to be deciphered. Here, we review the state of galectin literature in the B cell compartment, particularly with regard to B cell development, activation, differentiation, and effector function. We also discuss how differential glycosylation in B cells serves to regulate galectin function during different stages of B cell maturation. Finally, we conclude with emerging roles of galectins in B cell-mediated immune disease, particularly autoimmune disease.

Galectins: Structure and Function {#s2}
=================================

The glycan binding functions of galectins are mediated by highly conserved carbohydrate recognition domains (CRDs), which favor binding to β-galactoside-containing glycans, especially N-acetyllactosamines and their derivatives ([@B1]). To date, 15 galectins have been identified in mammals, classified based on their structure as either prototype, chimera-type, or tandem-repeat type ([@B1]). Prototype galectins, which includes galectins (Gal)-1,-2,-5,-7,-10,-11,-13,-14, and -15, possess one CRD and typically form homodimers by non-covalent association([@B1], [@B10]--[@B12]). Chimera-type galectins, of which Gal-3 is the only family member identified to date, possess a single CRD connected to a collagen-like oligomerization domain that facilitates formation of higher order pentamers ([@B13]). Tandem-repeat type galectins include Gal-4,-8,-9, and -12 and contain two distinct CRDs that are covalently joined by a variable linker region ([@B1], [@B14]). The precise specificity of individual galectins varies somewhat between family members, and each galectin generally shows preference for a restricted set of glycoconjugates ([@B1]). Although galectins can function intracellularly, galectins predominantly operate at the cell surface and in endosomal compartments through interaction with membrane glycoconjugates ([@B1], [@B15]). Paradoxically, galectins lack a canonical secretion signal and therefore how galectins transit to the cell surface remains a major unresolved question in the field ([@B1]). Regardless of galectin structure and specificity, a unifying property is their capacity for bivalent or multivalent binding, which permits formation of galectin-glycoprotein networks called "lattices" that regulate glycoconjugate membrane dynamics ([@B16]--[@B18]). By tuning glycoprotein compartmentalization, diffusion speed, internalization, and lateral association with other glycoconjugates, galectins impact many critical cellular processes, especially signal transduction ([@B16], [@B17]). In some cases, the outcomes of galectin binding can be contradictory due to the vast diversity of galectin ligands, the binding of which can be modulated by the cell\'s metabolic, transcriptional, or glycosylation state ([@B1]). Therefore, the physiological functions of galectins are highly contextual, and consequently represent a dynamic mechanism to regulate immune cell activation and function.

Galectins in B Cell Development {#s3}
===============================

Galectins are recognized as regulators of thymic T cell development, with Gal-1,-3,-8, and -9 each reported to regulate thymocyte apoptosis and selection ([@B19]--[@B25]). However, a significant body of research has also amassed implicating galectins in early B cell development, particularly at the pre-BI to large pre-BII transition, when productively rearranged heavy chains pair with "surrogate" light chain ([@B26]) and the signaling chains CD79a/b (Igα/Igβ) form the pre-B cell receptor (pre-BCR) ([@B26], [@B27]). Signaling through the pre-BCR serves as a developmental checkpoint critical for pre-B cell expansion and development. However, whether signaling occurs by ligand-independent or ligand-dependent mechanisms has been a matter of debate ([@B26]).

Accumulating evidence suggests Gal-1 may serve ligand-like properties, albeit non-essential, in pre-BCR signaling. Using a combination of pulldown assays with recombinant surrogate light chain and surface plasmon resonance, Gauthier et al. identified that Gal-1 binds to the λ5 component of the surrogate light chain ([@B28]). In this and subsequent functional studies, Gal-1 was found to be produced by specialized bone marrow stromal cells that interact with pre-B cells, augmenting pre-BCR signaling by enhancing pre-BCR clustering at the pre-B cell/stromal cell synapse ([@B28]--[@B33]). Unusually, while Gal-1-mediated clustering of pre-BCR unequivocally depends on interactions between Gal-1 and several glycosylated pre-B cell integrins, binding of Gal-1 to surrogate light chain is not glycan-dependent ([@B28], [@B31], [@B33]). Instead, Gal-1 was found to interact with the "unique region" of λ5 via non-glycan-mediated hydrophobic interactions ([@B34]). Taken together, a model has emerged in which bone marrow stromal cell-secreted Gal-1 binds pre-B cell glycans expressed on integrins and facilitates pre-B cell / stromal cell synapse formation, while non-CRD-mediated interactions between Gal-1 and surrogate light chain subsequently promote pre-BCR clustering and signaling. However, it should be noted that the overall significance of Gal-1 to B cell development *in vivo* remains somewhat unresolved, as B cell development is minimally impaired in Gal-1-deficient mice ([@B26], [@B30]). How Gal-1 may overlap with other regulators of pre-BCR signaling, including heparan sulfates ([@B35], [@B36]), as well as with ligand-independent mechanisms of pre-BCR signaling, remains to be conclusively determined. Current paradigms suggest that both Gal-1-dependent and Gal-1-independent mechanisms jointly contribute to efficient pre-BCR signaling, and may exert compensatory activity ([@B26]).

Besides Gal-1, Gal-3 has also been implicated as a potential regulator of bone marrow B cell development. *LGALS3-/-* mice exhibit abnormal levels of several developing B cell subsets, including CD19+ B220+ c-Kit+ IL-7R+ pro-B cells ([@B37]). Accordingly, Gal-3-deficiency also correlated with dramatically augmented production of IL-7 transcript and increased levels of Notch ligands Jagged-1 and Delta-like 1 by bone marrow stroma in *LGALS3-/-* mice ([@B37]). While the precise mechanism was not investigated, these data suggest Gal-3 may act on bone marrow stroma to shape B cell development.

Galectins in B Cell Signaling and Activation {#s4}
============================================

In addition to the growing body of literature implicating a role for galectins in B cell development, emerging evidence suggests that galectins play important roles in the regulation of B cell signaling and activation. To date, Gal-1,-3, and-9 have each been implicated as both positive and/or negative regulators of B cell signaling.

In a recent study, Tsai et al. found that Gal-1 induces stimulatory signaling in murine B cells that bears hallmarks of antigen-receptor signaling through the BCR. They found that Gal-1 induces calcium flux, upregulation of B cell activation markers CD69 and CD86, and proliferation ([@B38]). Furthermore, using a phospho-proteomic approach, the authors observed that activation by Gal-1 leads to similar phosphorylation circuits as stimulation through IgM. Studies analyzing the role of Gal-1 *in vivo* revealed impaired proliferation of Gal-1-deficient B cells in response to antigenic challenge. Interestingly, Gal-1 from non-B cell sources was required for optimal B cell activation, as Gal-1 sufficient B cells in Gal-1 deficient hosts also showed reduced proliferation *in vivo*. Importantly, however, several groups have also reported that although Gal-1 is not highly expressed in resting mature B cells, it is highly upregulated with B cell activation, making the relevant contribution of B cell-intrinsic vs. B cell-extrinsic Gal-1 uncertain ([@B39]--[@B42]). In studies of B cell chronic lymphocytic leukemia (B-CLL) which depend on BCR signaling for survival and proliferation, Croci et al. observed that specialized tumor-supporting monocytes, so called "nurse-like" cells, enhanced BCR signaling and survival through the production of Gal-1 ([@B43]). Specifically, the authors found that Gal-1 bound B-CLL cells in a glycan-dependent manner and lowered the threshold of productive BCR signaling. Gal-1 also simultaneously promoted B-CLL survival through Gal-1-mediated enhancement of BAFF and APRIL expression by nurse-like cells. Collectively, these findings suggest a model where exogenous, and possibly B cell-intrinsic Gal-1, promote B cell activation through a BCR-dependent mechanism.

Paradoxically, however, in a few studies, Gal-1 has also been implicated as a negative regulator of B cell activation. In a study by Tabrizi et al. Gal-1 was highly expressed by resting and especially activated IgM+ memory B cells, inhibited Akt signaling, and promoted B cell death ([@B40]). Another study of human BL36 Burkitt lymphoma cells found that Gal-1 directly bound CD45 and inhibited its phosphatase activity ([@B44]). In mammalian two hybrid studies from the Roeder laboratory, Gal-1 was also found to bind (in a non-glycan-dependent mechanism) the B cell transcriptional co-activator and promoter of BCR signaling Oca-B, which the authors hypothesized inhibited cytoplasmic Gal-1 secretion and prevented Gal-1 induced suppression of CD45 phosphatase activity ([@B41]). Thus, the physiological functions for Gal-1 in B cells may be diverse, complex, and context dependent ([@B44]).

Besides Gal-1, many studies have implicated Gal-3 in the regulation of B cell activation. In a recent study by Beccaria et al. Gal-3 was also found to modulate B cell activation and germinal center (GC) immune responses. Specifically, the authors observed that Gal-3 was expressed in resting splenic B cells at steady state, and loss of Gal-3 in *LGALS3-/-* mice resulted in heightened activation (measured by CD80 and CD86 expression), spontaneous GC formation, augmented antibody secreting cell numbers, and increased circulating IgG2c and IgG3 ([@B45]). This phenotype was B cell-intrinsic, as adoptive transfer of *LGALS3-/-* B cells into B-cell deficient (but otherwise Gal-3-sufficient) mice showed similar results, as well as in other corroborating studies with *LGALS3-/-* B cells *in vitro*. Although the effects of Gal-3 were B cell-intrinsic, interplay between GC B cells and follicular T helper cells was postulated to be important, and IFNγ (produced most prominently by T cells but also B cells) was essential for spontaneous B cell GC formation. Additionally, data from several other studies of *LGALS3-/-* mice seem to support the overall conclusions of Beccaria et al., with *LGALS3-/-* showing overall improved antibody responses in several models of parasite infection, including *Plasmodium yoelii* ([@B46]) and *Schistosoma mansoni* infection models ([@B37], [@B45], [@B47]--[@B50]), but not *Plasmodium berghei* and *Plasmodium chabaudi* infection ([@B46]). Although a clear understanding of the molecular mechanisms involved is still lacking, studies of the role of Gal-3 in human diffuse large B cell lymphoma cell lines have shown that Gal-3 binds CD45, dampens its phosphatase activity, and promotes lymphoma cell survival ([@B51]). Interestingly, Gal-3 is known to be downregulated in primary human GC B cells ([@B52]), suggesting that loss of Gal-3 may be important for altering CD45 signaling activity within GCs, where CD45 is known to be essential for GC persistence ([@B53]). Additional studies will be required to decipher the molecular mechanisms operating that may restrict B cell activation.

In addition to Gal-3, Gal-9 has recently emerged as a negative regulator of BCR signaling and activation. Gal-9 was first implicated in the regulation of B cell activation in studies analyzing Gal-9-deficient mice, where Sharma et al. observed that mice lacking Gal-9 have increased viral-specific IgM, IgG, and IgA titers as well as enhanced formation of antibody secreting cells in response to influenza A challenge ([@B54]). These initial data were further supported by studies in human B cells, which demonstrated that recombinant and mesenchymal stem cell-derived Gal-9 antagonizes B cell proliferation and antibody-secreting cell formation in a dose dependent manner, and that treatment of mice with recombinant Gal-9 *in vivo* resulted in diminished antigen specific serum titers in response to immunization ([@B55]).

Recently, our groups independently investigated the molecular mechanisms for Gal-9 mediated regulation of B cell activation ([@B56], [@B57]). We found that Gal-9 is detectable on the surface of primary naïve B cells in both mice and humans and could act in a B cell-intrinsic manner to negatively regulate BCR signaling. Mechanistically, Gal-9 antagonized BCR signal transduction by similar but slightly different mechanisms. In human B cells, we found that a major Gal-9 receptor was CD45 ([@B57]). Binding of CD45 by Gal-9 triggered a negative signaling cascade through Lyn, CD22, and SHP-1 that dampened BCR-triggered calcium flux and inhibited activation of calcium-sensitive transcription factors, including NFAT-1 and NF-κB. In an analogous but distinct manner, in murine B cells, we observed that Gal-9 bound not only CD45 but also IgM-BCR ([@B56]). Functionally, murine Gal-9 regulated BCR-antigen microclustering and downstream signaling, both of which were enhanced in Gal-9-deficient murine B cells. However, rather than altering calcium signaling, murine Gal-9 mitigated activation of CD19 and ERK1/2 downstream of BCR ligation. We hypothesize that this impaired signaling response is due to Gal-9\'s ability to prevent exclusion of inhibitory receptors from the signalosome, as we found CD45 and CD22 are specifically enriched within Gal-9 lattices and showed enhanced colocalization with IgM-BCR. Moreover, using dual-color super-resolution microscopy, we observed that association of IgM-BCR with CD22 is reduced in resting Gal-9-deficient B cells, and propose that this provides a plausible mechanism for enhanced BCR signaling in the absence of Gal-9 ([@B56]). Taken together these data suggest that Gal-9 acts to attenuate BCR signaling through facilitating interactions with endogenous regulatory networks (Figure [1](#F1){ref-type="fig"}). These findings provide exciting potential for therapeutic development targeting steady-state B cell signaling networks.

![Galectin-9 regulates B cell receptor signaling in human and murine B cells through analogous but distinct mechanisms. Naïve B cell activation is antagonized by Gal-9 through binding to the receptor tyrosine phosphatase CD45 on human B cells that activates a Lyn-CD22-SHP-1 dependent circuit and inhibits calcium accumulation downstream of the BCR \[Left, orange asterisks (\*)\]. In murine B cells, Gal-9 similarly regulates BCR signaling by altering the nanoscale organization of signaling molecules. Specifically, Gal-9 has been found to bind CD45 but also IgM BCR, preventing exclusion of CD45 and CD22 upon B cell activation and leading to impaired signal transduction following BCR ligation \[Left, blue asterisks (\*)\]. In humans, Gal-9 binding activity is differentially regulated between naïve and germinal center (GC) B cells via concerted alterations in N-glycosylation. Specifically, Gal-9 binding has been shown to be greatly diminished in germinal center (GC) B cells via upregulation of the glycosyltransferase GCNT2, which catalyzes I-branch formation on glycan ligands of Gal-9 (poly-LacNAcs), and attenuates Gal-9 binding ([@B56], [@B57]).](fimmu-09-02839-g0001){#F1}

Galectins as Modulators of B Cell Differentiation and Cell Fate {#s5}
===============================================================

An accumulating body of evidence suggests that galectins can also influence cell fate decisions in mature B cells, particularly in regulating the balance of B cell differentiation to memory or plasma cells.

Acosta-Rodriguez et al. examined the role of Gal-3 in B cells both *in vitro* and *in vivo* following *Trypanosoma cruzi* infection ([@B58]). The authors found that Gal-3 was upregulated in response to IL-4 or CD40-mediated stimulation and in B cells during ongoing parasite infection *in vivo*. Silencing of Gal-3 by RNA interference *in vitro* and *in vivo* prevented IL-4-induced downregulation of Blimp-1, a transcription factor critical for plasma cell development, and enhanced plasma cell differentiation. A mechanism was proposed in which Gal-3 works in concert with IL-4 to disfavor plasma cell differentiation and promote differentiation to memory B cells ([@B58]). Indeed, this hypothesis has since been supported by numerous studies demonstrating increased antibody-secreting cell numbers and antibody titers at steady state and in response to parasite infection in *LGALS3--/--* mice ([@B37], [@B45]--[@B50]). Interestingly, B-lymphopenia, significantly disrupted follicular architecture in lymph nodes and spleen, increased spontaneous GC numbers, and lupus-like pathology have also been reported for *LGALS3--/--* mice ([@B45], [@B47], [@B48], [@B50]).

In contrast to Gal-3, data suggests that Gal-1 and Gal-8 favor plasma cell fate decisions. Studies examining Gal-1 expression in murine and human B cells have noted that Gal-1 is significantly upregulated with B cell differentiation and is directly induced by Blimp-1 ([@B39], [@B59]). Through a combination of *in vitro* approaches that included ectopic expression, genetic knockdown, synthetic galectin inhibitors, and use of galectin-deficient mice, Tsai et al. demonstrated Gal-1 is sufficient to positively regulate plasma cell differentiation *in vitro* ([@B39], [@B59]). However, the authors propose that Gal-1 is not strictly required, as Gal-8 was found to be able to functionally compensate for loss of Gal-1 ([@B39]). In a separate study, however, Anginot et al. demonstrate that, at least *in vivo*, Gal-1 is required for optimal plasma cell responses and may not be fully compensated by Gal-8 ([@B60]). Specifically, Gal-1-deficient mice exhibited impaired antibody secreting cell number and diminished IgM and IgG titers in response to immunization, particularly in response to the T-dependent antigens ([@B60]). Interestingly, both groups report that Gal-1 is produced by ([@B39], [@B59], [@B60]) and binds ([@B39], [@B59]) only early plasma cells and not fully differentiated plasma cells, suggesting that Gal-1 and -8 drive the earliest stages of plasma cell differentiation. While the specific mechanism of action remains unresolved, Gal-1 and Gal-8 expression and/or treatment were associated with enhanced expression of XBP-1 (Gal-1 and Gal-8), Blimp-1 (Gal-8), IL-10 (Gal-1), and IL-6 (Gal-8) ([@B39]). In addition, Gal-1 also appears to have pro-survival roles in plasma cells ([@B60]). By contrast, Gal-1 has been reported to be expressed by IgM+ memory B cells, in which it was shown to inhibit Akt signaling compared to Gal-1^lo^ naïve B cells and promote BCR-induced apoptosis ([@B40]). Thus, Gal-1/-8 and Gal-3 appear to have opposing roles in skewing the outcome of B cell differentiation.

Galectins in B Cell Effector Function {#s6}
=====================================

Galectins have also been reported to have roles in the regulation of B cell effector function. As secreted molecules, galectins can exert cytokine-like activity. A documented example is Gal-1, which is upregulated with B cell activation and secreted into the B cell milieu, where it has been shown to induce apoptosis of inflammatory T cells ([@B42]). Besides serving as effector cytokines, galectins have also been reported to augment the immunoglobulin secretion capacity of plasma cells. Although Gal-1 and Gal-8 facilitate plasma cell differentiation (described earlier), they also have been shown to directly enhance secretion of antibody by augmenting expression of XBP-1s and by increasing the ratio of secreted / membrane IgM transcripts ([@B39], [@B59]). Once secreted, antibodies themselves can be bound by galectins. Both Gal-3 and Gal-9 have been shown to bind IgE bound to mast cell FcεR and prevent clustering-induced degranulation of inflammatory mediators ([@B61]--[@B63]).

Glycosylation in the Regulation of Galectin Activity {#s7}
====================================================

As lectins, extracellular galectin activity is often highly dependent on the favorable glycosylation of target receptors ([@B1]). Receptor glycosylation is regulated by a host of factors, including cell metabolism, ER and Golgi nucleotide sugar-donor transporters, and the rate of glycoprotein flux through the Golgi ([@B64]). Frequently, however, receptor glycosylation is dictated by the expression and activity of relevant ER- and Golgi-resident glycosyltransferases, glycosidases, and glycan-modifying enzymes.

Recently, our laboratory analyzed the global N-glycan repertoire of human tonsillar naïve, GC, and memory B cells by whole glycome mass spectrometry (MS) and plant lectin based flow cytometry ([@B57]). We found that all three B cell subsets expressed tri- and tetra-antennary complex-type N-glycans replete with poly-N-acetyllactosamine (poly-LacNAc), which are repeating units of the disaccharide N-acetyllactosamine (Gal-GlcNAc) that canonically serve as high affinity binding determinants for many galectins. Indeed, poly-LacNAc expression by naïve and memory B cells corresponded with robust binding to Gal-1 and, to our surprise, Gal-9, which had previously not been reported to bind B cells. However, whereas Gal-1 showed similarly strong binding to GC B cells as non-GC cell types, Gal-9 binding was starkly reduced in GC B cells. Closer examination of the N-glycomic profile of naïve, GC, and memory B cells by tandem MS revealed that many poly-LacNAcs in GC B cells were modified with internal β1,6 GlcNAc- and galactose-containing disaccharides, termed "I-branches" or I-blood group antigen, that were not present in naïve and memory B cells ([@B57]). I-branch expression at the GC stage corresponded with upregulated expression of the I-branching enzyme, GCNT2, and genetic studies in B cell lines demonstrated that GCNT2/I-branches were both necessary and sufficient to inhibit Gal-9 binding ([@B57]), as well as Gal-3 binding \[([@B65]) and unpublished observations\] (Figure [1](#F1){ref-type="fig"}). Interestingly, Gal-1 binding was largely unaffected by I-branches, suggesting that I-branches may preferentially target Gal-3 and Gal-9 glycan binding motifs, whereas terminal modifications such as α2,6-sialylation by the sialyltransferase ST6Gal1 may more selectively target Gal-1 ([@B1], [@B8]). Therefore, selective glycosyltransferase expression may be a mechanism of disparately regulating the activity of different galectin family members in B cells.

Beyond I-branches, regulation of Core 2 poly-LacNAc expression on O-glycans by GCNT1 was shown by Clark et al. to be a major factor controlling Gal-3 binding in B cell lines ([@B51]). Whereas B cell lines expressing GCNT1 showed robust binding and cell surface localization of Gal-3, B cells with inherently low GCNT1 or GCNT1 knockdown did not ([@B51]). Although the expression pattern of GCNT1 in native B cell populations was not determined, studies in our laboratory ([@B66]) indicate that naïve and GC B cells robustly express GCNT1/Core 2 poly-LacNAcs, whereas more differentiated B cells (memory B cells and plasmablasts) downregulate GCNT1/Core 2 poly-LacNAcs. The significance of this glycan expression pattern to Gal-3 binding activity is currently under investigation by our laboratory.

It is important to emphasize that while glycosylation can significantly contribute to the regulation of galectin activity, not all galectin functionality is exclusively glycan-dependent. In a study by Bonzi et al., it was demonstrated that non-glycosylation dependent interactions between Gal-1 and pre-BCR induce conformational changes in the Gal-1 CRD in a manner that alter its glycan-binding preferences, perhaps allowing Gal-1 to disengage from glycosylated integrin ligands and promote non-glycosylation dependent pre-BCR clustering. Moreover, galectins have been shown to exhibit roles intracellularly in mitochondrial, cytoplasmic, and nuclear compartments ([@B15]).

As novel functions emerge for galectins in B cells, identifying the factors regulating their activity, especially expression of favorable glycan ligands, will remain crucial to understanding their physiological role *in vivo*, and how galectin-glycan interactions may be exploited therapeutically.

Galectins in B Cell Autoimmunity {#s8}
================================

The increasingly apparent roles for galectins in modulating B cell activation and cell fate suggests that galectins may serve important roles as regulators of B cell tolerance. While clearly a budding and ongoing area of investigation, a few studies have suggested potential (albeit complex) roles for Gal-1, Gal-3, and Gal-9 in B cell-mediated autoimmune disease ([@B67]). Recent evidence suggests that Gal-3 deficient mice develop systemic autoimmunity with lupus-like features, including spontaneous GC formation, elevated levels of anti-nuclear antibodies, and kidney pathology ([@B45]). This lupus-like pathology became increasingly pronounced with age, and was found to be absolutely dependent on B cell-intrinsic Gal-3 as well as IFNγ, the production of which was increased in both B cells and T cells ([@B68]). Of note, studies by Clark et al. also noted autoantibody development in *LGALS3--/--* mice when crossed to LamH transgenic mice, which express an antibody heavy chain reactive against the self-antigen laminin ([@B69]). Interestingly, the numbers of autoreactive B cells that escape tolerance mechanisms are increased further in mice doubly deficient for both Gal-3 and Gal-1 ([@B69]). While specific mechanisms linking Gal-3, and possibly Gal-1, to maintaining B cell tolerance have yet to be fully elucidated, it should be noted that both Gal-3 and Gal-1 have been shown to be more highly expressed in anergic murine B cells ([@B68]).

Besides Gal-1 and Gal-3, Gal-9 has also been implicated in the development of lupus-like disease in several models of SLE. In a recent study, Panda *et al*. demonstrated that treatment of BXSB/MpJ and (NZB × NZW)F1 lupus-prone mice with Gal-9 before symptoms manifests diminishes the probability of developing pathology, including tissue inflammation and splenomegaly associated with disease onset ([@B70]). Mechanistically, the authors present evidence that Gal-9 antagonizes TLR7- and TLR9-dependent activation of plasmacytoid dendritic cells (pDCs) and B cells, as well as type I Interferon production by pDCs. In a second study from Moritoki et al., Gal-9 was found to ameliorate pathology in a MRL/lpr model of lupus, apparently by inducing plasma cell apoptosis, although a direct link was not firmly established ([@B71]). Interestingly, these two studies are seemingly opposite to findings from Zeggar et al., who using a pristane-induced lupus model, observed that *LGALS9--/--* mice exhibited reduced disease burden and unaltered TLR7-type I interferon signaling ([@B72]). The reasons underlying these disparate results are unclear, but may reflect the different model systems used, including spontaneous *vs*. inducible models of lupus and disparate moue backgrounds ([@B73]). Future studies will be required to parse the precise contribution of Gal-9, Gal-3, and Gal-1 to B cell tolerance, and to better determine a possible role for these lectins (or relevant glycans) in the development of autoimmune disease in humans.

Conclusions and Outlook {#s9}
=======================

Here, we have reviewed the emerging roles of galectins in B cell immunobiology. Over the past two decades, studies have revealed a complex network of positive and negative regulatory roles for galectins acting throughout B cell development, activation, differentiation, and antibody responses (Figure [2](#F2){ref-type="fig"}). Recent studies in particular have highlighted novel roles for Gal-9 and glycosylation in the regulation of BCR signaling and activation. Moving forward, studies investigating the precise mechanisms of galectin function in B cells, and concomitant regulation of galectin activity by B cell glycosylation, will be of great interest. Furthermore, how galectins contribute to B cell-mediated disease, including autoimmune disease, will remain a critical area of future research that will likely yield important insights into disease etiology and/or novel therapeutic approaches targeting galectin-glycan interactions. Undoubtedly, the continued investigation of the multitudinous and complex roles of galectins in B cell biology will be an exciting pursuit in the years ahead.

![Galectins regulate B cell development, activation, and differentiation. Depicted are published roles of galectins at various stages of differentiation, as well as reported expression of galectins and galectin-binding glycans. Orange asterisks (\*) indicate findings described in human B cells, and blue asterisks (\*) indicate findings observed in mice. Bone marrow B cells ([@B28]--[@B34], [@B37], [@B60]); naïve B cells ([@B38], [@B43], [@B45], [@B56], [@B57]); anergic B cells ([@B37], [@B68]); GC B cells ([@B45], [@B51]); memory B cells ([@B37], [@B40], [@B45]--[@B50], [@B58]); plasmablasts and plasma cells ([@B37], [@B39], [@B59], [@B60]).](fimmu-09-02839-g0002){#F2}
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